Transfection of NF-κB decoy oligodeoxynucleotide suppresses pulmonary metastasis by murine osteosarcoma

Cancer Gene Therapy

Volumn 18, Issue 4, 2011, Pages 250-259

  Nishimura, A ^a   Akeda, K ^a   Matsubara, T ^a   Kusuzaki, K ^a   Matsumine, A ^a   Masuda, K ^b   Gemba, T ^c   Uchida, A ^a   Sudo, A ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AnGes MG Inc   (Japan)

Author keywords

nuclear factor kappa B; osteosarcoma; synthetic double stranded oligodeoxynucleotide

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NAKED DNA; OLIGODEOXYNUCLEOTIDE DERIVATIVE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BONE NEOPLASMS; GENE THERAPY; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C3H; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; OSTEOSARCOMA; TRANSFECTION; TUMOR CELLS, CULTURED;

MURINAE;

EID: 79952898337     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.75     Document Type: Article

References (47)

1. Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosar-coma patients. Cancer 1997; 79: 411-415. (Pubitemid 27029907)
2. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995; 80: 529-532.
3. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683. (Pubitemid 26130197)
4. Ravi R, Bedi A. NF-kappaB in cancer-a friend turned foe. Drug Resist Updat 2004; 7: 53-67. (Pubitemid 38453836)
5. Meyskens Jr FL, Buckmeier JA, McNulty SE, Tohidian NB. Activation of nuclear factor-kappa B in human metastatic melanoma cells and the effect of oxidative stress. Clin Cancer Res 1999; 5: 1197-1202. (Pubitemid 29233238)
6. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-3639. (Pubitemid 27281838)
7. Yokoo T, Kitamura M. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 1996; 270: F123-F130.
8. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-4023. (Pubitemid 27281877)
9. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13: 62-69. (Pubitemid 46067387)
10. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188-4197. (Pubitemid 32762193)
11. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000; 6: 2573-2581. (Pubitemid 30399230)
12. Andela VB, Sheu TJ, Puzas EJ, Schwarz EM, O'Keefe RJ, Rosier RN. Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFkappaB. Biochem Biophys Res Commun 2002; 297: 237-241. (Pubitemid 35216160)
13. Andela VB, Siddiqui F, Groman A, Rosier RN. An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF kappa B in human osteosarcoma. J Clin Pathol 2005; 58: 328-330. (Pubitemid 40380335)
14. Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H et al. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002; 93: 296-304. (Pubitemid 34464366)
15. Harimaya K, Tanaka K, Matsumoto Y, Sato H, Matsuda S, Iwamoto Y. Antioxidants inhibit TNFalpha-induced moti-lity and invasion of human osteosarcoma cells: possible involvement of NFkappaB activation. Clin Exp Metastasis 2000; 18: 121-129. (Pubitemid 32165245)
16. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007; 13: 59-67. (Pubitemid 46121853)
17. Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 2007; 211: 555-562. (Pubitemid 46502432)
18. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A et al. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-899. (Pubitemid 27353450)
19. Morishita R, Tomita N, Kaneda Y, Ogihara T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 2004; 4: 139-146. (Pubitemid 38444048)
20. Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S et al. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999; 6: 91-97. (Pubitemid 29043698)
21. Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 2001; 8: 905-912. (Pubitemid 32600146)
22. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S et al. Establishment and characterization of a murine osteosarco-ma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998; 76: 418-422. (Pubitemid 28282943)
23. Akeda K, Nishimura A, Satonaka H, Shintani K, Kusuzaki K, Matsumine A et al. Three-dimensional alginate spheroid culture system of murine osteosarcoma. Oncol Rep 2009; 22: 997-1003.
24. Dunn TB, Andervont HB. Histology of some neoplasms and non-neoplastic lesions found in wild mice maintained under laboratory conditions. J Natl Cancer Inst 1963; 31: 873-901.
25. Masuda K, Takegami K, An H, Kumano F, Chiba K, Andersson GB et al. Recombinant osteogenic protein-1 upregulates extracellular matrix metabolism by rabbit annulus fibrosus and nucleus pulposus cells cultured in alginate beads. J Orthop Res 2003; 21: 922-930. (Pubitemid 37045572)
26. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 2001; 29: E21.
27. Imai Y, Miyamoto K, An HS, Thonar EJ, Andersson GB, Masuda K. Recombinant human osteogenic protein-1 upregulates proteoglycan metabolism of human anulus fibrosus and nucleus pulposus cells. Spine 2007; 32: 1303-1309;discussion 1310. (Pubitemid 46791448)
28. Matsumine A, Shintani K, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T et al. Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol 2007; 96: 411-418. (Pubitemid 47519447)
29. Horiuchi K, Morioka H, Nishimoto K, Suzuki Y, Susa M, Nakayama R et al. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer Lett 2008; 272: 336-344.
30. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M et al. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 2009; 278: 145-155.
31. Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M et al. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol 2006; 29: 713-719.
32. Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells. Expert Rev Anticancer Ther 2003; 3: 793-798. (Pubitemid 37540536)
33. Zucchini C, Rocchi A, Manara MC, De Sanctis P, Capanni C, Bianchini M et al. Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines. Int J Oncol 2008; 32: 17-31. (Pubitemid 351176058)
34. Um JH, Kwon JK, Kang CD, Kim MJ, Ju DS, Bae JH et al. Relationship between antiapoptotic molecules and meta-static potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J Pharmacol Exp Ther 2004; 311: 1062-1070. (Pubitemid 39612712)
35. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
36. Huang WC, Chan ST, Yang TL, Tzeng CC, Chen CC. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis 2004; 25: 1925-1934.
37. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999; 35: 1089-1093. (Pubitemid 29339192)
38. Lin YC, Shun CT, Wu MS, Chen CC. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006; 12: 7165-7173.
39. Tannock IF, Hill RP, Bristow RG, Harrington L. Tumor Progressin and Metastasis: Cellular, Molecular, and Micro-environment Factors. In: Khokha R, Voura E, Hill RP (eds). The Basic Science of Oncology, Fourth edn The McGraw-Hill Companies, Inc.: New York, 2004, pp 205-230.
40. Roque F, Mon G, Belardi J, Rodriguez A, Grinfeld L, Long R et al. Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA). Antisense Nucleic Acid Drug Dev 2001; 11: 99-106. (Pubitemid 32378314)
41. Miyao T, Takakura Y, Akiyama T, Yoneda F, Sezaki H, Hashida M. Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res Dev 1995; 5: 115-121.
42. Higuchi Y, Kawakami S, Oka M, Yabe Y, Yamashita F, Hashida M. Intravenous administration of mannosylated cationic liposome/NFkappaB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model. FEBS Lett 2006; 580: 3706-3714. (Pubitemid 43902808)
43. De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T et al. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2007; 56: 524-533. (Pubitemid 46580509)
44. Desmet C, Gosset P, Pajak B, Cataldo D, Bentires-Alj M, Lekeux P et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 2004; 173: 5766-5775. (Pubitemid 39392166)
45. Inagaki H, Suzuki J, Ogawa M, Taniyama Y, Morishita R, Isobe M. Ultrasound-microbubble-mediated NF-kappaB decoy transfection attenuates neointimal formation after arterial injury in mice. J Vasc Res 2006; 43: 12-18. (Pubitemid 41832706)
46. Azuma H, Tomita N, Sakamoto T, Kiyama S, Inamoto T, Takahara K et al. Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer 2008; 122: 1645-1656. (Pubitemid 351294976)
47. Matsubara T, Akeda K, Nishimura A, Kusuzaki K, Matsumine A, Shintani K et al. Injection of naked decoy oligodeoxynucleotide against nuclear factor-kappa B into a murine osteosarcoma in a spontaneous pulmonary metastasis model. Trans Orthop Res Soc 2008; 33: 1196.